Durham, NC (PRWEB) May 08, 2013
Treatment with neoadjuvant 5-FU, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) followed by chemoradiation shows substantial activity in patients with locally advanced pancreatic cancer, with conversion to surgical resectability with curative intent in more than 20% of patients. In a retrospective study published in The Oncologist, Jason Faris, M.D., Medical Oncologist at the Massachusetts General Hospital Cancer Center in Boston, and colleagues described their institutional experience with the FOLFIRINOX treatment protocol in patients with locally advanced pancreatic cancer.
Nearly one-third of patients with newly diagnosed pancreatic cancer present with locally advanced disease, which is associated with a median overall survival of approximately one year. Effective treatment of locally advanced pancreatic cancer may permit resection for patients with initially unresectable disease, but to date no standard of care has been defined for this patient population. Although treatment with FOLFIRINOX is associated with improved response rate, progression-free survival, and overall survival in the metastatic setting, this regimen has not been studied extensively in patents with locally advanced pancreatic cancer.
The current study included all patients (n = 22) with locally advanced prostate cancer who began treatment with FOLFIRINOX between July 2010 and February 2012 at the Massachusetts General Hospital Cancer Center. The neoadjuvant FOLFIRINOX regimen consisted of 5-FU administered as a bolus of 400mg/m2, bolus leucovorin 400mg/m2 followed by continuous infusion at 1200mg/m2/day for 46 hours, oxaliplatin 85mg/m2, and irinotecan 180mg/m2. For 20 patients, FOLFIRINOX was followed by chemoradiation with continuous infusion 5-FU or capecitabine and intensity-modulated radiation therapy (50.4 Gy).
Patients received a median of 8 cycles of neoadjuvant FOLFIRINOX, including a
Copyright©2012 Vocus, Inc.
All rights reserved